Showing results (761-770 of 1,983) with videos related to
Sort By:
Pageof 199
The Lancet. Neurology|March 17, 2007
Stroke epidemiology, prevention, and management strategies at a regional level: Latin America and the CaribbeanPablo M Lavados, Anselm J M Hennis, Jefferson G Fernandes, et al.The Lancet. Neurology|June 1, 2007
A clinical prognostic scoring system for Guillain-Barré syndromeRinske van Koningsveld, Ewout W Steyerberg, Richard A C Hughes, et al.The Lancet. Neurology|April 25, 2006
The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort studyDavid A Bennett, Julie A Schneider, Yuxiao Tang, et al.The Lancet. Neurology|May 23, 2006
Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative studyRajiv Mohanraj, John Norrie, Linda J Stephen, et al.The Lancet. Neurology|May 23, 2006
Startle syndromesMirte J Bakker, J Gert van Dijk, Arn M J M van den Maagdenberg, et al.The Lancet. Neurology|May 23, 2006
Epidemiology of Parkinson's diseaseLonneke M L de Lau, Monique M B BretelerThe Lancet. Neurology|December 14, 2022
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional studyAnna H Boerwinkle, Brian A Gordon, Julie Wisch, et al.The Lancet. Neurology|November 18, 2019
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trialGregory L Krauss, Pavel Klein, Christian Brandt, et al.The Lancet. Neurology|January 22, 2019
Implications of sleep disturbance and inflammation for Alzheimer's disease dementiaMichael R Irwin, Michael V VitielloThe Lancet. Neurology|June 19, 2021
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trialJames F Howard, Vera Bril, Tuan Vu, et al.Pageof 199